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Abstract 46 
The hypoxia-inducible transcription factor HIF-1 is appreciated as a promising target for 47 
cancer therapy. However, conditional deletion of HIF-1 and HIF-1 target genes in cells of the 48 
tumor microenvironment can result in accelerated tumor growth, calling for a detailed 49 
characterization of the cellular context to fully comprehend HIF-1s role in tumorigenesis. We 50 
dissected cell type-specific functions of HIF-1 for intestinal tumorigenesis by lineage-51 
restricted deletion of the Hif1a locus. Intestinal epithelial cell-specific Hif1a loss reduced 52 
activation of Wnt/β-catenin, tumor-specific metabolism and inflammation, significantly 53 
inhibiting tumor growth. Deletion of Hif1a in myeloid cells reduced the expression of 54 
fibroblast-activating factors in tumor-associated macrophages resulting in decreased 55 
abundance of tumor-associated fibroblasts (TAF) and robustly reduced tumor formation. 56 
Interestingly, hypoxia was detectable only sparsely and without spatial association with HIF-57 
1α, arguing for an importance of hypoxia-independent, i.e. non-canonical, HIF-1 stabilization 58 
for intestinal tumorigenesis that has not been previously appreciated. This adds a further 59 
layer of complexity to the regulation of HIF-1 and suggests that hypoxia and HIF-1α 60 
stabilization can be uncoupled in cancer. Collectively, our data show that HIF-1 is a pivotal 61 
pro-tumorigenic factor for intestinal tumor formation, controlling key oncogenic programs in 62 
both the epithelial tumor compartment and the tumor microenvironment. 63 
64 
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Introduction 65 
Colorectal cancer (CRC) ranks as the fourth most common tumor in the western world, 66 
causing a substantial amount of cancer-associated morbidity and mortality [1]. The 67 
combination of molecular-targeted drugs with conventional chemotherapeutic agents 68 
significantly improved the therapeutic options for CRC patients [2]. However, as also noted 69 
frequently for other solid tumors, these new generation treatments rarely result in improved 70 
overall outcome, but rather benefit small subgroups of CRC patients [3]. Taken together, an 71 
urgent need to identify novel therapy targets exists, demonstrating the necessity for detailed 72 
characterization of the molecular CRC pathogenesis. 73 
 74 
The hypoxia-inducible transcription factor 1 (HIF-1) is positively associated with the 75 
malignant progression of various tumor entities [4]. While the role of HIF-1 for the 76 
pathogenesis of CRC has been addressed by different groups, results are conflicting and the 77 
precise function of HIF-1 for intestinal tumorigenesis remains elusive. Stabilization of HIF-1α, 78 
the regulatory component of HIF-1, in human CRC has been reported via 79 
immunohistochemistry, suggesting a pro-tumorigenic function [5-7]. In line with these 80 
findings, inhibition of HIF-1α in human CRC cell lines resulted in reduced xenograft growth 81 
[8, 9]. Furthermore, pharmaceutical inhibition of HIF-1 led to diminished growth of 82 
autochtonous as well as allograft murine CRC models via reduced angiogenesis and 83 
macrophage infiltration [10]. On the other hand, transgenic activation of HIF-1 in intestinal 84 
epithelial cells (IEC) remained without effect on tumor formation in murine models of sporadic 85 
and colitis-associated colon cancer [11, 12]. Moreover, IEC-specific loss of Hif1a did not 86 
affect tumor frequency in a chemical model of proximal intestinal tumorigenesis [13]. These 87 
results illustrate that the precise role of HIF-1 for intestinal tumorigenesis remains elusive 88 
thus far. 89 
 90 
While HIF-1 is widely appreciated as a promising target for cancer therapy, conditional 91 
deletion of HIF-1 and HIF-1 target genes in cells of the tumor microenvironment can result in 92 
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accelerated tumor growth [14-16]. Against this background, a comprehensive analysis of 93 
HIF-1s role in tumorigenesis in order to translate the findings into the clinic can only be 94 
achieved by considering the cell- and tissue-specific context. Here, we present a detailed 95 
deconstruction of HIF-1s role in CRC initiation and progression in IEC- and myeloid cell-96 
specific Hif1a knock-out mice [17, 18] using two murine models of intestinal tumor formation: 97 
Chemically-induced colon tumors (AOM/DSS (combination of azoxymethane plus dextran 98 
sulfate sodium for colitis-associated carcinogenesis) [19]) and the genetic APCmin model 99 
[20]. This experimental approach enabled us to address the role of HIF-1 in neoplastic 100 
epithelial cells as well as in innate immune cells of the tumor microenvironment. We were 101 
able to unravel numerous specialized functions of HIF-1. In IECs, HIF-1 serves to induce 102 
inflammation, control Wnt/β-catenin activity and regulate tumor-specific metabolism. In 103 
addition, we identified myeloid HIF-1 as essential for the activation of tumor-associated 104 
fibroblasts. Of note, intratumoral hypoxia was a rare event, pointing towards an importance of 105 
hypoxia-independent, i.e. non-canonical HIF-1 stabilization for intestinal tumorigenesis [21]. 106 
Collectively, our data show that HIF-1 is a pivotal pro-tumorigenic factor, controlling key 107 




Epithelial Hif1a controls intestinal tumor growth on multiple levels 112 
IEC-specific loss of Hif1a (termed Hif1aIEC) was established by breeding villin-cre mice [22] 113 
with animals harbouring homozygously floxed Hif1a alleles [18]. Conditional Hif1a deletion 114 
was characterized on various levels and found to be highly efficient (Figure S1A). Tumor size 115 
in both the AOM/DSS and APCmin model was significantly decreased in Hif1aIEC mice (Figure 116 
1A). While proliferation was not different between the genotypes (data not shown), Hif1aIEC 117 
adenomas displayed significant differences regarding the number of apoptotic tumor cells 118 
(Figure S1B) and CD31-positive endothelial cells as well as Vegfa expression (Figure S1C), 119 
pointing towards a functional importance of HIF-1α in tumor cells for resistance towards 120 
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apoptosis and angiogenesis. To further analyze the mechanisms underlying the reduced 121 
tumor size in Hif1aIEC mice, we first characterized the activity of the Wnt/β-catenin pathway, 122 
the central oncogenic driver of CRC. As can be seen in figure 1B-D, the expression of 123 
selected β-catenin target genes is significantly reduced in adenomas of Hif1aIEC mice. Of 124 
note, nuclear translocation of β-catenin was not affected by the Hif1a KO (Figure S1D). 125 
Furthermore, the expression of TCF-1 and LEF-1, two pivotal binding partners for β-catenin 126 
that have been characterized as HIF-1 targets by the group of Celeste Simon in murine 127 
embryonic stem and teratocarcinoma cells [23] was independent of HIF-1 in murine intestinal 128 
adenomas (Figure S1E). While these results strongly suggest a functional role of HIF-1 for 129 
Wnt/β-catenin activity in murine intestinal tumorigenesis, the underlying molecular 130 
mechanisms remain elusive at this point. Next, we addressed the role of Hif1a for tumor-131 
specific glucose metabolism as metabolic reprogramming represents an emerging hallmark 132 
of cancer and several glycolytic enzymes are transcriptionally controlled by HIF-1 [24]. Mass 133 
spectrometry-based analysis of intratumoral glucose levels, routing of 13C-labelled glucose 134 
as well as in vivo imaging by PET/CT revealed diminished uptake and metabolization into 135 
lactate of glucose in tumors of Hif1aIEC mice (Figure 1E, F). Finally, we performed a 136 
comprehensive analysis of inflammatory activity as chronic inflammation is pro-tumorigenic in 137 
CRC [25]. Hif1aIEC mice displayed reduced loss of body weight (Figure 2A) and colitis activity 138 
after DSS challenge (Figure 2B). Intestinal gene expression and protein secretion of pro-139 
inflammatory factors were significantly lower in DSS-treated Hif1aIEC mice (Figure 2C, D). We 140 
included a characterization of mucins as these evolutionary preserved glycoproteins are of 141 
crucial importance innate immune responses in the gut [26]. As Muc1, 2 and 3 can be 142 
regulated by HIF-1 [27-29], we investigated their gene expression patterns and found no 143 
difference under basal conditions. In contrast, Muc1 and 3 were strongly upregulated by DSS 144 
in a HIF-1α-dependent manner (Figure S2A). Quantification of the inflammatory infiltrate via 145 
immunohistochemistry did not show significantly reduced numbers of macrophages, 146 
granulocytes, T cells and Tregs after DSS in the colon of Hif1aIEC animals (Figure S2B). This 147 
at first suprising result is in line with published findings demonstrating that clinical and 148 
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biochemical inflammation markers do not necessarily overlap with the cellular infiltrate in the 149 
DSS model [30]. Experiments with small intestinal organoids were conducted to further 150 
address the specific contribution of IECs in this setting. After assuring efficient Hif1a deletion 151 
(Figure S2C), organoids were subjected to different pro-inflammatory stimuli. These 152 
experiments nicely confirmed that the pro-inflammatory response of IECs critically depends 153 
on Hif1a (Figure 2E). Taken together, these data point towards a complex role for Hif1a in 154 
IECs during intestinal tumor formation, comprising resistance to apoptosis, angiogenesis, 155 
Wnt/β-catenin activity, metabolic reprogramming and inflammation. 156 
 157 
Hif1a in myeloid cells regulates intestinal tumor formation independent of 158 
inflammation 159 
Macrophages in the tumor microenvironment exert a number of tumor-supporting functions 160 
and are positively associated with the malignant phenotype [31]. We and others have shown 161 
that Hif1a is of pivotal importance for various aspects of macrophage function [17, 32]. 162 
Against this background, we sought to characterize the role of Hif1a in macrophages for 163 
intestinal tumor formation. We found that myeloid cell-specific loss of Hif1a (termed Hif1aMC) 164 
resulted in a highly significant reduction of both tumor number and size (Fig. 3A). In order to 165 
identify the underlying mechanisms, we first analyzed the inflammatory response. Rather 166 
unexpectedly, various assays of inflammation (e.g. determination of weight loss (Fig. 3B), 167 
disease activity index (Fig. 3C)) as well as gene expression and protein secretion of 168 
established pro-inflammatory markers (Fig. 3D-F)) failed to show a significant difference 169 
between wildtype and Hif1aMC mice. 170 
 171 
Hif1a-deficient tumor-associated macrophages migrate and function normally 172 
Next, we determined intratumoral macrophage numbers via immunohistochemistry (IHC). 173 
While macrophage abundance was clearly greater in adenomas compared to surrounding 174 
normal mucosa (not shown), no difference was detectable between the genotypes (Figure 175 
4A). Intestinal leukocyte subsets were subsequently analyzed in more detail by flow 176 
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cytometry. Tumor-bearing mice displayed a prominent increase in CD11c+ macrophages and 177 
CD11b+ dendritic cells, while CD11c- macrophages were reduced. The changes in myeloid 178 
subsets were comparable between wildtype and Hif1aMC mice, except for a slightly more 179 
pronounced reduction of CD11c- intestinal macrophages in tumor-bearing Hif1aMC mice 180 
(Figure 4B). Intestinal lymphoid cell populations did not differ significantly between wildtype 181 
and Hif1aMC mice (Figure 4B). Notably, tumor-bearing animals showed typical alterations of 182 
extraintestinal myeloid cells [33], including increase of monocytes in blood and bone marrow 183 
and accumulation of Gr1+ CD11b+ myeloid-derived suppressor cells (MDSC) in bone 184 
marrow, but not spleen (Figure S3). Extraintestinal myeloid cells did not differ between 185 
wildtype and Hif1aMC mice. Next, we decided to analyze the direct tumor-supporting action of 186 
macrophages as these cells secrete numerous pro-tumorigenic factors [34]. To this end, 187 
spheroids of APCmin adenomas were stimulated with conditioned medium (CM) from primary 188 
murine macrophages. While we were able to detect a significant growth-promoting effect of 189 
macrophage CM, the loss of Hif1a did not affect the outcome (Figure 4C). As macrophages 190 
represent pivotal modulators of stem-like/progenitor cells [35], which are critical drivers of 191 
colonic carcinogenesis [36], we decided to quantify these cells in our experimental setting. 192 
Visualization of Lgr5 and Prox1, two established progenitor/stem-cell markers in intestinal 193 
tumors [37, 38], demonstrated robust presence of these cells in AOM/DSS adenomas, albeit 194 
without differences between the genotypes (Figure S4A). We took into consideration that 195 
other cells of myeloid origin might underlie the reduced tumor formation in Hif1aMC mice. 196 
While mast cells can influence intestinal tumorigenesis under certain experimental conditions 197 
[39], no difference in intratumoral abundance of this cell type was noted, arguing against a 198 
functional importance of mast cells in our setting (Figure S4B). 199 
 200 
Hif1a in myeloid cells is essential for the activation of tumor-associated fibroblasts 201 
Myeloid cells in the tumor microenvironment are known to interact with various cell types, 202 
including tumor-associated fibroblasts (TAF). These cells are abundant in human CRC and 203 
significantly impact on disease progression [40, 41]. TAFs were readily detectable via IHC in 204 
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the stroma of APCmin and AOM+DSS-induced adenomas (Figure 5A). Strikingly, deletion of 205 
Hif1a in myeloid cells resulted in greatly reduced numbers of TAFs in both tumor models 206 
(Figure 5A). This result pointed towards a crucial role of Hif1a in myeloid cells for TAF 207 
development. Interestingly, the importance of macrophages for fibroblast activation in the 208 
context of wound healing is well established [42, 43]. To analyze this further, we focussed on 209 
alternatively activated macrophages (AAM) given their central role in the control of organ 210 
fibrosis [42]. Expression of various pro-fibrotic genes in AAMs was readily detectable, but 211 
loss of Hif1a remained without greater effect (Figure S5A). To achieve experimental data that 212 
more closely resemble the in vivo situation, we analyzed pro-fibrotic factor expression in 213 
tumor-associated macrophages (TAM) directly isolated from intestinal adenomas. This 214 
approach indeed unravelled a central role of Hif1a in TAMs for the expression of various 215 
fibroblast-activating factors, e.g. COX-2, IGF-1, IL-1β and granulin (Figure 5B). In our 216 
analyses, the expression of TGF-β1, the archetypical pro-fibrotic factor, was constantly lower 217 
in Hif1a-null TAMs, but did not reach statistical significance (Figure 5B). As the activation of 218 
TGF-β1 is a complex and highly regulated process [44], we hypothesized that HIF-1α is of 219 
importance in this setting. Indeed, HIF-1α-deficient AAMs displayed reduced levels of 220 
bioactive TGF-β in the supernatant (Figure 5C), suggesting a functional importance of HIF-221 
1α for TGF-β activity elicited by TAMs. Next, we addressed the role of Hif1a for macrophage-222 
mediated fibroblast proliferation [42, 45]. While conditioned medium from AAM enhanced 223 
survival of primary murine intestinal fibroblasts (MIFs), no difference between WT and Hif1a-224 
deficient macrophages was detectable (Figure S5B). Finally, we sought to address the 225 
secretion of pro-tumorigenic cytokines, another tumor-promoting function of TAFs [46]. 226 
Stimulation of primary MIFs with conditioned medium from AAM induced gene expression of 227 
IL-6, HGF and epiregulin (Ereg), factors with established tumor-promoting activity in the 228 
intestine [47, 48]. Of note, this effect was significantly reduced upon deletion of Hif1a in 229 
macrophages (Figure 5D). 230 
 231 
Myeloid-mediated activation of TAF precursor cells depends on Hif1a 232 
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TAFs can originate from different cellular sources, amongst others pericytes, mesenchymal 233 
stems cells (MSCs) and fibrocytes [46]. We sought to investigate if macrophages are able to 234 
polarize these cell types into myofibroblasts and whether Hif1a is important in this setting. 235 
Gli1-positive pericytes, marked by tdTomato expression [49], as well as MSCs readily 236 
polarized into myofibroblasts after addition of macrophage conditioned medium (CM, Figure 237 
6A and B). Intriguingly, HIF-1α was of central importance in this setting as the effect on 238 
pericytes was completely and that on MSCs partially abolished upon Hif1a deletion. 239 
Fibrocytes are of myeloid origin, display features of monocytes as well as fibroblasts and 240 
contribute to fibrosis in various organs and tumors [50, 51]. We took advantage of an 241 
established protocol to generate fibrocytes ex vivo from splenic monocytes [52]. Of note, 242 
Hif1adeficient monocytes displayed greatly reduced capacity for fibrocyte production 243 
(Figure 6C). Furthermore, the expression of various tumor-supporting factors in fibrocytes 244 
was found to be regulated by Hif1a (Figure 6D). Taken together, these results point to a 245 
hitherto unknown function of Hif1a for the activation of TAF precursor cells of different origin. 246 
 247 
Non-canonical stabilization of HIF-1α predominates in murine intestinal tumors  248 
The luminal cell layer of the colon is characterized by physiological hypoxia [53]. Nuclear 249 
HIF-1α protein is readily detectable in luminal enterocytes (Figure S6A), suggesting hypoxia-250 
induced HIF-1α protein stabilization in the gut under physiological conditions. Against this 251 
background, we sought to determine the relevance of hypoxia for HIF-1α protein stabilization 252 
in murine intestinal tumors. Intriguingly, hypoxic areas were detected only sporadically in 253 
AOM+DSS and APCmin adenomas (Figure 7A and B). This pattern of hypoxia was clearly not 254 
able to explain the pervasive stabilization of HIF-1α protein in both tumor types. Of note, 255 
hypoxia-independent means of HIF-1α protein stabilization have been identified and are 256 
gradually receiving more attention [21, 24]. As activation of various oncogenes has been 257 
shown to result in hypoxia-independent HIF-1 stabilization [24], we decided to investigate the 258 
role of oncogenes and tumor suppressor genes characteristic for colon cancer [54]. To mimic 259 
the molecular events that instigate tumor formation in the APCmin model, mice with inducible 260 
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Apc deletion were analyzed [55]. Of note, acute Apc loss resulted in enhanced HIF-1α 261 
protein stability (Figure 7D). To analyze the role of oncogene activation for HIF-1a 262 
stabilization, we took advantage of transgenic mice with doxycycline-inducible, epithelial-263 
specific expression of oncogenes with relevance for CRC pathogenesis [56, 57]. The 264 
strongest effect was noted for PIK3CAH1047R, the activation of which resulted in robust HIF-1α 265 
protein stabilization of the entire epithelial cell lining (Figure 7E). Induction of oncogenic 266 
KRASG12V or degradation-resistant β-catenin resulted in localized HIF-1α stabilization in 267 
luminal epithelial cells (Figure 7F,G). These results point towards a functional role of key 268 
tumor suppressors and oncogenes regulating the Wnt/β-catenin, phosphatidylinositol-3-269 
kinase and mitogen-activated protein kinase cascades for non-canonical HIF-1α stabilization 270 
during intestinal tumor formation and progression. 271 
 272 
Discussion 273 
Here, we addressed the functional importance of HIF-1 for colon cancer in a cell type-specific 274 
manner, using transgenic mice harbouring either an intestinal epithelial cell- (Hif1aIEC) or a 275 
myeloid cell-specific (Hif1aMC) Hif1a deletion [17, 18, 22]. We found that Hif1a plays multiple 276 
non-redundant roles in these two key cell types of intestinal tumors (summarized in Figure 277 
S8). Our finding of reduced tumor growth in Hif1aIEC mice is in line with earlier reports 278 
showing Hif1a-dependent growth of human CRC xenografts [8, 9]. Also in line with our 279 
results, the group of Celeste Simon reported that application of a chemical HIF inhibitor 280 
decreased tumor formation in mice bearing AOM+DSS adenomas and s.c. CT26 allografts 281 
[10]. Of note, transgenic overexpression of oxygen-stable HIF-1α in intestinal epithelial cells 282 
did not further accelerate the formation of AOM+DSS and APCmin tumors [11]. Deletion of 283 
Hif1a in IECs did not affect tumor size in a chemical model of proximal colon cancer [13], 284 
arguing for the importance of cell type- and location-specific factors that need to be further 285 
investigated. 286 
 287 
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In our experiments, Hif1aIEC mice displayed lower levels of pro-inflammatory cytokines in 288 
acute DSS-induced colitis, suggesting an activating function of HIF-1 in IECs for intestinal 289 
inflammation. This result contrasts with earlier reports from various independent groups. 290 
Karhausen et al. noted enhanced activity in hapten-induced intestinal inflammation upon 291 
conditional loss of Hif1a in IECs [53] and identified reduced barrier integrity in mutant mice as 292 
the underlying mechanism. Against this background, we determined intestinal barrier function 293 
in our mice and could not find a difference between WT and Hif1aIEC mice (Figure S7). Later, 294 
Shah et al. reported no effect of IEC-specific Hif1a loss on the severity of acute DSS-induced 295 
colitis [58]. It is well established that the susceptibility to experimentally induced colitis is 296 
genetically determined and differs substantially between inbred strains of mice [59]. 297 
Karhausen et al. and Shah et al. used mice with a mixed genetic background while our mice 298 
were >99% C57Bl6/J, potentially explaining the different results. Additional support for a 299 
protective role of HIF-1 during intestinal inflammation came from two simultaneously 300 
published seminal reports by the groups of Sean Colgan and Cormac Taylor showing that 301 
inhibitors of prolyl hydroxylases (PHDs), a group of enzymes crucial for HIF degradation, 302 
protect against murine colitis [60, 61]. In our opinion, different explanations are possible 303 
regarding the conflict with our data, e.g. a functional importance of other PHD targets, e.g. 304 
NF-κB, and hydroxylase-independent functions of PHD inhibitors. Furthermore, systemically 305 
administered PHD inhibitors target every cell they encounter while in our genetic model HIF-306 
1 was exclusively deleted in IECs, precluding a direct comparison of the different 307 
experimental approaches. Regarding Hif1a in myeloid cells, we did not observe significant 308 
changes in DSS-induced intestinal inflammation and this is well in line with data from a 309 
Korean group [62]. On the contrary, Sandra Winning, Joachim Fandrey and colleagues 310 
reported protective roles for Hif1a in myeloid [63] and dendritic cells [64] upon DSS 311 
challenge. Of note, Kim et al. could not detect a functional importance of Hif1a in myeloid 312 
cells for AOM+DSS-induced tumor formation, clearly contrasting with our data [62]. The 313 
exact mechanisms for these opposing results remain elusive at this time. 314 
 315 
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Our analysis of mucin gene expression confirms earlier reports showing induction of mucin 316 
gene expression by DSS [65] and the notion that Muc1 and 3 are direct targets of HIF-1α 317 
[27, 29]. Complementing the published work, we were able to show that HIF-1α is essential 318 
for DSS-induced gene expression of Muc1 and 3 in murine intestinal eptithelial cells. In 319 
contrast, our results do not support a functional relevance of HIF-1α in IECs for basal 320 
expression of these mucin isoforms. Taken together, these data argue for a causal role of 321 
HIF-1-induced Muc1 and 3 for the inflammatory response to DSS, a notion well in line with 322 
the established importance of mucins for innate immunity [66]. 323 
 324 
Seminal work in the laboratory of Randall Johnson had shown that HIF-1α is essential for 325 
myeloid cell-mediated inflammation and that Hif1a-deficient macrophages fail to migrate 326 
towards pro-inflammatory cues [17]. Our results contrast with this observation as we did not 327 
detect reduced macrophage abundance in tumors of Hif1aMC mice. However, our data are 328 
well in line with a later study from the Johnson lab demonstrating no effect of the myeloid 329 
cell-specific Hif1a KO on the abundance of F4/80-positive macrophages in a murine breast 330 
cancer model [67]. The precise reason(s) for this discrepancy must remain elusive at this 331 
time, but context- and model-specific factors could well play a significant role. It is 332 
conceivable that infiltration of macrophages into tumors is not as sensitive to Hif1a deletion 333 
as tissue infiltration in the context of inflammation. In addition, it is possible that proliferation 334 
of local macrophages compensates for reduced macrophage infiltration into KO adenomas 335 
[68]. This would result in a situation where the findings by Cramer et al. [17] and Doedens et 336 
al. [67] would be well in line with our current data. 337 
 338 
Our findings support a central role of HIF-1α in myeloid cells for the activation of fibroblasts 339 
in the stroma of intestinal tumors. In the context of wound healing and organ fibrosis, the 340 
importance of macrophages, especially that of alternatively activated macrophages (AAM), 341 
for fibroblast activation is well established [69, 70]. AAMs are of special significance as they 342 
express various fibroblast-activating factors [42]. While earlier reports showed a functional 343 
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relevance of HIF-1 for the control of gene expression of pro-fibrotic factors (e.g. TGF-β1, 344 
endothelin-1, fibronectin-1 and COX-2 [71-74]) in different cell types, Hif1a deletion in AAMs 345 
remained without effect on mRNA expression of a comprehensive set of pro-fibrotic factors in 346 
our experimental setup. To address the importance of the tissue context, we isolated tumor-347 
associated macrophages (TAMs) from intestinal adenomas. Of note, in these cells the 348 
expression of various pivotal pro-fibrotic genes was indeed regulated by Hif1a. These results 349 
not only underscore the significance of Hif1a for TAM-mediated activation of TAFs, but again 350 
illustrate the importance of experimental conditions that more closely resemble the tissue 351 
context. 352 
 353 
TAFs were for the longest time unequivocally considered to support tumor growth and 354 
progression [46]. This concept was recently challenged by reports from three independent 355 
groups, showing accelerated tumor progression upon either genetic ablation of αSMA-356 
positive TAFs or attenuated stroma formation in murine pancreatic ductal adenocarcinoma 357 
[75, 76]. At first glance, this observation contrasts with our data arguing for a tumor-358 
supporting role of TAFs. Besides cancer type- and context-specific factors, the different 359 
experimental approaches are strong candidates for potential explanations. The group of 360 
Raghu Kalluri used an elegantly designed genetic model resulting in direct ablation of TAFs. 361 
Our experimental setup, on the other hand, targeted TAFs indirectly via deletion of Hif1a in 362 
myeloid cells. The studies by Ozdemir et al. and Rhim et al. point towards previously 363 
unappreciated tumor-inhibiting functions of TAFs. How pro- and anti-tumor aspects of TAFs 364 
are regulated is an intriguing question. While our data suggest that myeloid Hif1a impacts 365 
mainly on tumor-supporting aspects of TAFs, future work has to address the eligibility of HIF-366 
1 inhibitors in the setting of a stroma-targeting cancer therapy. 367 
 368 
Our study highlights that HIF-1α can be stabilized by multiple means in the colon cancer 369 
context. We show that loss of APC, as well as oncogenic activation of PIK3CA or KRAS in 370 
intestinal epithelial cells is followed by HIF-1α stabilization. Our findings give credence to the 371 
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concept of non-canonical HIF-1α stabilization that was recently coined by Amato Giaccia and 372 
colleagues [21]. It is important to note that we cannot exclude a role for hypoxia downstream 373 
of the genetic changes and that this study has not determined the exact molecular link(s) 374 
relaying oncogenic events to HIF-1α stabilization. However, our data add a further layer of 375 
complexity to HIF-1α regulation, and suggest that hypoxia and HIF-1α stabilization can be 376 




Materials and methods 381 
Animals and Mouse models 382 
In all experiments, male and female mice were divided randomly into homogeneous groups 383 
according to their weight, age and sex (VillinCre/Hif1aloxP/loxP, VillinCre/Hif1aloxP/loxP/APC+/min, 384 
LysMCre/Hif1aloxP/loxP and LysMCre/Hif1aloxP/loxP/APC+/min, all on a C57BL/6J background). For 385 
the AOM/DSS model, 6-8 week-old mice were injected intraperitoneally with 10 mg/kg AOM 386 
(azoxymethane; Sigma-Aldrich, Germany) followed by three cycles of 2% dextran sodium 387 
sulfate (DSS; MP Biomedicals, Germany) in drinking water for five days and normal drinking 388 
water for 16 days. Mice were sacrificed 8 weeks after AOM injection. Tumors were counted 389 
and measured under a dissecting microscope by a blinded investigator and colonic normal 390 
and tumor tissue snap frozen in liquid nitrogen for ex vivo analysis. In the acute DSS model, 391 
10-12 week-old mice received 2% DSS in the drinking water for 6 days and were sacrificed 392 
on the last day of DSS administration. In order to assess DSS colitis activity, body weight, 393 
stool consistency and the presence of occult or gross blood were determined and a scoring 394 
system was applied [77]. Spheroids of APC+/min mice were cultured as described [78]. 395 
Oncogene-inducible mice have been described before [56, 57]. For histology, small 396 
intestines and colons were removed, flushed with PBS, fixed in 10% neutral buffered formalin 397 
at 4°C overnight and paraffin-embedded. Experimentation and transgenic animal generation 398 
was approved by authorities in Berlin (Landesamt für Gesundheit und Soziales: G0004/07, 399 
G0185/09, G0143/14). 400 
 401 
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Isolation and stimulation of bone marrow-derived macrophages (BMDM)  402 
Bone marrow was collected from tibiae, femurs and humeri of 8-12 weeks old wildtype and 403 
Hif1aMC mice. After flushing out the marrow, red blood cells were lysed with ACK buffer and 404 
cells were seeded on plastic plates in RPMI supplemented with 10% FBS, 100 U 405 
penicillin/ml, 100 ȝg/ml streptomycin. Next day, non-attached cells were collected and 406 
cultured in RPMI supplemented with 20% FBS and 30% L929-conditioned medium for one 407 
week. Differentiated BMDMs were stimulated for 48 h with LPS (100 ng/ml, Sigma Aldrich) 408 
and γ-IFN (20 ng/ml) for classically activated (CAM) and with IL-4 (20 ng/ml, both from 409 
eBioscience) for alternatively activated macrophages (AAM). For RNA isolation, cells were 410 
harvested using TRIzol (Invitrogen) from M0 (non-polarized), CAM and AAM. To collect 411 
conditioned media from polarized macrophages, cells were extensively washed with PBS 48 412 
h after stimulation and fresh media was added for an additional 24 h. 413 
 414 
Flow cytometric analyses of murine leukocyte populations 415 
Small intestine was rinsed thoroughly and incubated in buffer containing EDTA to remove the 416 
mucus. Cells were minced and digested with type IV collagenase (Cellsystems). Blood was 417 
taken from the right ventricle. Small intestine, blood, bone marrow, and spleen cells were 418 
subjected to red blood cell lysis using Pharm Lyse (BD Biosciences, San Jose, USA). Flow 419 
cytometric analysis was done as described in detail before [79]. Antibodies were purchased 420 
from eBioscience (F4/80, #25-4801-82, CD3e, #25-0031-82, CD4, #17-0042-82 and CD8a, 421 
#25-0081-82), BD Biosciences (CD45, #557659, CD11b, #550993, Ly6G, #551460, CD19, 422 
#551001, CD107a, #553793, NK1.1, #553165, Gr1, #552093 and I-Ab, #553552) and 423 
Biolegend (CD11c, #117312 and CD103, #121420). 424 
 425 
Statistical analysis 426 
Sample sizes were determined according to our experience in previous experiments and no 427 
statistical methods were used for predetermination. All experimental samples were included 428 
in the final analyses. Unless indicated otherwise, all data were representative of at least two 429 
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independent experiments and expressed as means + SEM. Before statistical analysis, data 430 
were checked for normal distribution (Shapirow Wilk test) and comparable variance (F-test 431 
for equality of variances for data with normal distribution). Comparisons between two groups 432 
of normally distributed data with equal variances were performed using the unpaired two-433 
sided Student`s t test. Differences were considered statistically significant at p<0.05. Sample 434 
size, statistical tests and p values are indicated in the figure legends. The asterisks in the 435 
graphs indicate statistically significant changes with p values: * p < 0.05, ** p≤0.01 and *** 436 
p≤0.001. Statistical analysis was done using Prism 4.0 software (GraphPad Software, San 437 
Diego, California, USA). 438 
 439 
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Figure Legends 775 
Figure 1. HIF-1α in IECs controls intestinal tumor formation, Wnt/ȕ-catenin activity and 776 
glucose metabolism. (A) Tumor number and size of WT and Hif1aIEC mice in the AOM/DSS 777 
(left, n = 7 per group) and APCmin model (right, n = 7 per group). (B) Relative mRNA 778 
expression of Wnt/ȕ-catenin target genes in colon tumors of WT and Hif1aIEC mice following 779 
AOM/DSS treatment (n = 3 biological replicates with technical duplicates). (C) RNA in-situ 780 
hybridization of the Wnt/ȕ-catenin target gene Axin2 in AOM/DSS adenomas of WT and 781 
Hif1aIEC mice. (D) Relative mRNA expression of Wnt/ȕ-catenin target genes in WT and 782 
Hif1aIEC APCmin tumors (n = 3 biological replicates with technical duplicates). (E) Glucose 783 
levels (left) and FDG-PET/CT analysis (right) of AOM/DSS-induced colon tumors (white 784 
arrow) of WT and Hif1aIEC mice (n = 7 per group). (F) Metabolization of glucose into lactate 785 
(left, n = 4 per group) and citrate (right, n = 13 per group) in colon tumors of WT and Hif1aIEC 786 
mice following AOM/DSS treatment determined by stable isotope-resolved metabolomics. 787 




Figure 2. IEC-specific deletion of Hif1a reduces intestinal inflammation. (A) Body weight 792 
change of WT and Hif1aIEC mice following AOM/DSS treatment (n = 14 per group), (B) 793 
disease activity index (n = 5 per group), (C) relative mRNA expression of inflammatory genes 794 
in colon tissues (n = 3 biological replicates with technical duplicates) and (D) secretion of 795 
cytokines by colonic explants of WT and Hif1aIEC mice on day 6 of acute DSS treatment (n = 796 
5 per group). (E) Pro-inflammatory cytokine mRNA expression in small intestinal organoids 797 
from WT and Hif1aIEC mice. Shown are mean and standard deviation of technical duplicates 798 
from one representative experiment (no statistical analysis performed). Unless indicated 799 
otherwise, data are represented as mean + SEM. *p<0.05; **p<0.01; ***p<0.001 by unpaired 800 
two-sided Students t test. 801 
  802 
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Figure 3. Hif1a in myeloid cells controls intestinal tumor formation without affecting 803 
inflammation. (A) Tumor number and size in WT and Hif1aMC mice after AOM/DSS 804 
administration (left, (n = 4 per group) and in the APCMin model (right, n = 5 per group). (B) 805 
Body weight change of WT (n = 7) and Hif1aMC (n = 8) mice following AOM/DSS treatment. 806 
(C) Disease activity index (n = 5 per group), (D) Relative mRNA expression of inflammatory 807 
genes in colon tissues (n = 3 biological replicates with technical duplicates) and (E) Secretion 808 
of cytokines by colonic explants of WT and Hif1aMC mice on day 6 of acute DSS treatment (n 809 
= 5 per group). (F) Relative mRNA expression of inflammatory genes in intestinal tissues of 810 
WT and Hif1aMC control (n = 3 biological replicates with technical duplicates) and APCmin 811 
mice (n = 4 biological replicates with technical duplicates). Data are represented as mean + 812 
SEM. *p<0.05; **p<0.01 by unpaired two-sided Students t test. 813 
 814 
 815 
Figure 4. Tumoral abundance of macrophages and stimulation of adenoma growth ex 816 
vivo is not affected by loss of Hif1a. (A) Representative F4/80 stainings of intestinal 817 
sections obtained from AOM/DSS-treated (above) and APCmin (below) WT and Hif1aMC mice. 818 
Right, quantification of F4/80-positive cells (n = 6 per group). (B) Total leukocytes were 819 
isolated from small intestines of wildtype and Hif1aMC mice remaining either untreated or 820 
bearing APCmin adenomas and analyzed by flow cytometry (n = 4 per group). Relative 821 
numbers of different subtypes are shown. Flow cytometric analyses of the CD11c- 822 
macrophage subset (I-Ab+, CD11c-, CD11b+, CD103-, F4/80+), the CD11c+ macrophage 823 
subset (I-Ab+, CD11c+, CD11b+, CD103-, F4/80+) and the CD11b+ dendritic cell subset (I-824 
Ab+, CD11c+, CD11b+, CD103+, F4/80-) were performed. Lymphoid leukocytes of the small 825 
intestine were subdivided into T cells (CD4+, CD8+) and NK cells (CD3-, NK1.1+). (C) Effect 826 
of macrophage conditioned media (CM) on spheroid formation from APCmin adenomas. Left, 827 
representative image of spheroids after stimulation. Quantification of spheroid number 828 
(middle) and diameter (right) after stimulation with conditioned media from WT and Hif1a-KO 829 
macrophages (n = 2 per group). Data in A and B are represented as mean + SEM. *p<0.05 830 
by unpaired two-sided Students t test. C right shows mean ± SD. 831 
Rohwer et al., HIF-1 and intestinal tumorigenesis 
 27
Figure 5. Hif1a in myeloid cells is essential for activation and pro-tumorigenic gene 832 
expression of intestinal fibroblasts. (A) Immunohistochemical analysis of myofibroblast 833 
markers αSMA and FSP-1 in intestinal sections from AOM/DSS-treated (above) and APCmin 834 
(below) WT and Hif1aMC mice. (B) Relative mRNA expression of pro-fibrotic genes in tumor-835 
associated macrophages isolated from APCmin adenomas from WT (n = 2 biological 836 
replicates with technical duplicates) and Hif1aMC (n = 4 biological replicates with technical 837 
duplicates) mice. (C) Determination of bioactive TGF-β in the supernatant of alternatively 838 
activated  WT and Hif1a-KO macrophages (n = 3 per group). (D) Relative mRNA expression 839 
of pro-tumorigenic genes in primary murine intestinal fibroblasts stimulated with conditioned 840 
media from WT and Hif1a-KO macrophages (n = 3 biological replicates with technical 841 
duplicates). Data are represented as mean + SEM. *p<0.05, **p<0.01 by unpaired two-sided 842 
Students t test. 843 
 844 
 845 
Figure 6. Myeloid cell-mediated activation of TAF precursor cells depends on Hif1a. 846 
(A) Representative images and quantification of Gli1+ MSC isolated from bone-chips of 847 
bigenic Gli1CreERt2;tdTomato mice and cultured with supernatants of CAM or AAM from 848 
either wildtype or Hif1aMC mice and stained for alpha smooth muscle actin (ĮSMA) indicating 849 
myofibroblast differentiation (n = 3 per group). (B) Mesenchymal stem cells were cultured in 850 
collagen gels for 14 days either in stem cell expansion medium (SCEM, control) or in a 851 
mixture of SCEM and supernatants of M0, CAM or AAM (n = 3 per group). Collagen gel 852 
areas were measured using the ImageJ software. (C) Representative images of fibrocytes 853 
differentiated in vitro from splenic monocytes from WT and and Hif1aMC mice. Magnification 854 
25x (upper panel) and 100x (lower panel). (D) Relative mRNA expression of selected pro-855 
tumorigenic factors in differentiated fibrocytes from WT and and Hif1aMC mice (n = 3 856 
biological replicates with technical duplicates). Data are represented as mean + SEM. 857 
*p<0.05 by unpaired two-sided Students t test. 858 
  859 
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Figure 7. Non-canonical stabilization of HIF-1α in murine intestine. (A) 860 
Immunofluorescent analysis of hypoxyprobe (red) and HIF-1α (green) in AOM/DSS-induced 861 
(left) and APCmin (right) adenomas. (B) Analysis of relative number of cells in adenomas 862 
expressing either hypoxyprobe (HP) or HIF-1α. (C-G) Immunohistochemical staining of HIF-863 
1Į in intestinal sections from mice with inducible expression of firefly luciferase (C, FLUC), 864 
PIK3CAH1047R (E), KRASG12V (F), stabilized β-catenin G) or inducible loss of APC (D). Data in 865 
B show mean + SD, 4 adenomas from 2 mice per model were evaluated. **p<0.001 by 866 
unpaired two-sided Students t test. 867 
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